A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease
Author
Abstract
Suggested Citation
DOI: 10.2165/11588390-000000000-00000
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Chris P. Lee & Glenn M. Chertow & Stefanos A. Zenios, 2006. "A Simulation Model to Estimate the Cost and Effectiveness of Alternative Dialysis Initiation Strategies," Medical Decision Making, , vol. 26(5), pages 535-549, September.
- Andrew Palmer & William Valentine & Joshua Ray & Stephane Roze & Noemi Muszbek, 2007. "Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 161-168, June.
- Ivy Chow & Elkin Lemos & Thomas Einarson, 2008. "Management and Prevention of Diabetic Foot Ulcers and Infections," PharmacoEconomics, Springer, vol. 26(12), pages 1019-1035, December.
- Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
- Braden Manns & David Meltzer & Ken Taub & Cam Donaldson, 2003. "Illustrating the impact of including future costs in economic evaluations: an application to end‐stage renal disease care," Health Economics, John Wiley & Sons, Ltd., vol. 12(11), pages 949-958, November.
- de Wit, G.Ardine & Ramsteijn, Paul G & de Charro, Frank Th, 1998. "Economic evaluation of end stage renal disease treatment," Health Policy, Elsevier, vol. 44(3), pages 215-232, June.
- George Carides & Shahnaz Shahinfar & Erik Dasbach & William Keane & William Gerth & Charles Alexander & William Herman & Barry Brenner, 2006. "The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy," PharmacoEconomics, Springer, vol. 24(6), pages 549-558, June.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Mohsen Yaghoubi & Sonya Cressman & Louisa Edwards & Steven Shechter & Mary M. Doyle-Waters & Paul Keown & Ruth Sapir-Pichhadze & Stirling Bryan, 2023. "A Systematic Review of Kidney Transplantation Decision Modelling Studies," Applied Health Economics and Health Policy, Springer, vol. 21(1), pages 39-51, January.
- Bernadette Li & John Cairns & James Fotheringham & Rommel Ravanan, 2016. "Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(6), pages 659-668, July.
- Nikos Maniadakis & Mattias Ekman & Vasilios Fragoulakis & Vasiliki Papagiannopoulou & John Yfantopoulos, 2011. "Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 253-261, June.
- Pieter H. M. van Baal & Talitha L. Feenstra & Rudolf T. Hoogenveen & G. Ardine de Wit & Werner B. F. Brouwer, 2007. "Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a ‘perfect’ cost–utility ratio," Health Economics, John Wiley & Sons, Ltd., vol. 16(4), pages 421-433, April.
- Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
- Ellen Busink & Dana Kendzia & Fatih Kircelli & Sophie Boeger & Jovana Petrovic & Helen Smethurst & Stephen Mitchell & Christian Apel, 2023. "A systematic review of the cost-effectiveness of renal replacement therapies, and consequences for decision-making in the end-stage renal disease treatment pathway," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 377-392, April.
- Wolfgang C. Winkelmayer & Milton C. Weinstein & Murray A. Mittleman & Robert J. Glynn & Joseph S. Pliskin, 2002. "Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment," Medical Decision Making, , vol. 22(5), pages 417-430, October.
- Wenjuan Fan & Yang Zong & Subodha Kumar, 2022. "Optimal treatment of chronic kidney disease with uncertainty in obtaining a transplantable kidney: an MDP based approach," Annals of Operations Research, Springer, vol. 316(1), pages 269-302, September.
- Sigrid M Mohnen & Manon J M van Oosten & Jeanine Los & Martijn J H Leegte & Kitty J Jager & Marc H Hemmelder & Susan J J Logtenberg & Vianda S Stel & Leona Hakkaart-van Roijen & G Ardine de Wit, 2019. "Healthcare costs of patients on different renal replacement modalities – Analysis of Dutch health insurance claims data," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-14, August.
- Alexander V van Schoonhoven & Judith J Gout-Zwart & Marijke J S de Vries & Antoinette D I van Asselt & Evgeni Dvortsin & Pepijn Vemer & Job F M van Boven & Maarten J Postma, 2019. "Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-22, September.
- Alec Morton & Amanda I. Adler & David Bell & Andrew Briggs & Werner Brouwer & Karl Claxton & Neil Craig & Alastair Fischer & Peter McGregor & Pieter van Baal, 2016. "Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal," Health Economics, John Wiley & Sons, Ltd., vol. 25(8), pages 933-938, August.
- Hamraz Mokri & Ingelin Kvamme & Linda Vries & Matthijs Versteegh & Pieter Baal, 2023. "Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(5), pages 701-715, July.
- Anne-Line Couillerot-Peyrondet & Cléa Sambuc & Yoël Sainsaulieu & Cécile Couchoud & Isabelle Bongiovanni-Delarozière, 2017. "A comprehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in France: the importance of age, diabetes status, and clinical events," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(4), pages 459-469, May.
- Zlatana Nenova & Jennifer Shang, 2022. "Chronic Disease Progression Prediction: Leveraging Case‐Based Reasoning and Big Data Analytics," Production and Operations Management, Production and Operations Management Society, vol. 31(1), pages 259-280, January.
- Marie Kruse & Jan Sørensen & Dorte Gyrd-Hansen, 2012. "Future costs in cost-effectiveness analysis: an empirical assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 63-70, February.
- Michelle Tew & Philip Clarke & Karin Thursky & Kim Dalziel, 2019. "Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients," PharmacoEconomics, Springer, vol. 37(7), pages 931-941, July.
- Klas Kellerborg & Werner Brouwer & Matthijs Versteegh & Bram Wouterse & Pieter van Baal, 2021. "Distributional consequences of including survivor costs in economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 30(10), pages 2606-2613, September.
- Thomas W Ferguson & James Zacharias & Simon R Walker & David Collister & Claudio Rigatto & Navdeep Tangri & Paul Komenda, 2015. "An Economic Assessment Model of Rural and Remote Satellite Hemodialysis Units," PLOS ONE, Public Library of Science, vol. 10(8), pages 1-11, August.
- Chris P. Lee & Glenn M. Chertow & Stefanos A. Zenios, 2008. "Optimal Initiation and Management of Dialysis Therapy," Operations Research, INFORMS, vol. 56(6), pages 1428-1449, December.
- Afiatin & Levina Chandra Khoe & Erna Kristin & Lusiana Siti Masytoh & Eva Herlinawaty & Pitsaphun Werayingyong & Mardiati Nadjib & Sudigdo Sastroasmoro & Yot Teerawattananon, 2017. "Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia," PLOS ONE, Public Library of Science, vol. 12(5), pages 1-10, May.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:29:y:2011:i:10:p:839-861. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.